San Mateo County Logo
Share to Facebook Share to Twitter Bookmark and Share
File #: 20-226    Version: 1 Name:
Type: Resolution Status: Passed
File created: 3/9/2020 Departments: HEALTH
On agenda: 4/21/2020 Final action: 4/21/2020
Title: Adopt a resolution authorizing the County Purchasing Agent to issue purchase orders to Priority Healthcare, dba Curascript Specialty Distribution to provide intrauterine and implantable prescription devices for the term of April 1, 2020 through March 31, 2023, in an amount not to exceed $1,500,000.
Attachments: 1. 20200421_r_Priority Healthcare
Special Notice / Hearing: None__
Vote Required: Majority

To: Honorable Board of Supervisors
From: Louise F. Rogers, Chief, San Mateo County Health
Chester J. Kunnappilly, MD, Chief Executive Officer, San Mateo Medical Center
Subject: Issuance of Purchase Orders to Priority Healthcare dba Curascript Specialty Distribution

RECOMMENDATION:
title
Adopt a resolution authorizing the County Purchasing Agent to issue purchase orders to Priority Healthcare, dba Curascript Specialty Distribution to provide intrauterine and implantable prescription devices for the term of April 1, 2020 through March 31, 2023, in an amount not to exceed $1,500,000.

body
BACKGROUND:
As part of San Mateo County's commitment to women's health, San Mateo Medical Center (SMMC) offers a variety of intrauterine and implantable prescription devices that provide birth control for its patients.

DISCUSSION:
SMMC pharmacy has been purchasing intrauterine and implantable prescription devices for many years through vendor agreements with Priority Healthcare dba Curascript Specialty Distribution (Curascript). This vendor agreement now requires the Board's approval for SMMC to continue to purchase these devices because the annual spend has reached the County's $100,000 threshold. SMMC is also requesting the Board to waive the Request for Bid process because Curascript's Nexplanon, a prescription inserted on the inner side of a woman's upper arm, provides safe effective contraception for up to three years and is a sole source device not sold by any other vendor. This agreement is coming to the Board late due to prolonged negotiations.

The resolution has been reviewed and approved by County Counsel as to form.

It is anticipated that the insertion of these implantable prescription devices will prevent conception for up to 3 years more than 99% of the time.

PERFORMANCE MEASURE:
Measure
FY 2019-20 Estimated
FY 2020-21 Projected
Percentage of time that these implantable prescript...

Click here for full text